Title:
Innovation in the biopharmaceutical industry
Innovation in the biopharmaceutical industry
Author(s)
Kamada, Vitor
Advisor(s)
Nair-Reichert, Usha
Editor(s)
Collections
Supplementary to
Permanent Link
Abstract
Three aspects of the drug development process are little understood in the literature: 1) which type of organization has comparative advantage in conducting clinical trials, firms or nonprofit organization (NPOs)?; 2) what determines the timing of technological collaboration?; and 3) how the strategies making, allying, and buying R&D impact the probability of drug approval? Using data on over 20,000 clinical trials, 800 technological alliances, and 14,000 R&D projects, the main findings of this econometric study are: 1) firms complete each phase of clinical trial faster than nonprofit organizations; 2) licensor scientific and technological specialization is the main factor to speed up the technological collaboration; and 3) R&D projects developed by research alliance have higher probability of drug approval than internal R&D projects, but R&D projects originated from M&A have lower probability of drug approval than internal R&D projects. Together these findings inform policy makers and managers on how to foster the innovation performance in the biopharmaceutical industry.
Sponsor
Date Issued
2017-06-26
Extent
Resource Type
Text
Resource Subtype
Dissertation